Bio Green Med Solution, Inc.
BGMS
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $5.0M
$0.90
▼ -1.96%
P/E
—
Mkt Cap
$5.0M
52-Wk Range
$0.57–$7.18
52-Week Range
$0.57 - $7.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 85.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified revenue streams reducing sector-specific risk
- Strategic Malaysian market presence through Fitters acquisition
- Integrated approach combining healthcare and industrial safety expertise
- Growing portfolio of proprietary biopharmaceutical technologies
Bear Case
1 risk
- Low volatility (beta -0.4).
Growth
Stable outlook
Expansion of biopharmaceutical pipeline and R&D initiatives
Value
Valuation data unavailable
Momentum
Weak
-17.9% over 3m
Quality
Thin
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying BGMS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 18, 2026
AUG 13, 2026
Most recent quarter reported revenue of $336.0K. Reported EPS of -$0.08. Gross margin 23.5%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
-100%
-100%
+710%
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.0K
$0
$0
$0
$81.0K
$666.0K
$778.0K
$336.0K
Margins · last 8Q
Gross
23.5%
Operating
-124.4%
Profit
-120.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BGMS stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related